ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: FR-PO1051

Genome-Wide Donor-Recipient Genetic Differences Influence Renal Allograft Survival Independent of HLA

Session Information

Category: Transplantation

  • 1702 Transplantation: Clinical and Translational

Authors

  • Menon, Madhav C., Mount Sinai School of Medicine, Forest Hills, New York, United States
  • Zhang, Zhongyang, Icahn School of Medicine at Mount Sinai, New York, New York, United States
  • Zhang, Weijia, Mount Sinai School of Medicine, Forest Hills, New York, United States
  • Stahl, Eli A., Icahn School of Medicine at Mount Sinai, New York, New York, United States
  • Hao, Ke, Icahn School of Medicine at Mount Sinai, New York, New York, United States
  • Murphy, Barbara T., Icahn School of Medicine at Mount Sinai, New York, New York, United States
Background

Renal interstitial fibrosis (IF-TA) is a non-specific histologic entity identified in 30-40% of all allografts that fail. Transcriptomic studies of human allograft biopsies show that gene-signatures of ongoing alloimmune activity persist in these IF-TA lesions. Conventionally, anti-donor alloimmunity is attributed to HLA-mismatching. However, non-HLA loci have recently been shown to determine allo-recognition & responses.

Methods

We utilized unique genome-wide SNP array data encompassing Donor-Recipient pairs (D-R) from our recently completed multicenter GoCAR study [PI- Barbara Murphy] to study the role of D-R differences on death-censored allograft survival (DCGS) after excluding HLA-regions (n=385). We used ADMIXTURE analysis on genome-wide genotype data to plot the actual genomic race (AGR) of D-Rs using 1000-genome data (Fig-1). Long term survival data were obtained from UNOS/ANZDATA.

Results

AGR was more accurate than self-reported race (reclassifying 2.7-54% D-Rs among different races). Recipient AGR impacted DCGS in adjusted cox survival models (aHR-2.25 for African-American AGR), while donor AGR had minimal effect. Euclidean D-R genetic distance calculated from AGR significantly associated with DCGS. HLA-matching did not impact DCGS in adjusted analysis. In D-R pairs of similar ancestry, proportion of genome-shared identity-by-descent (pIBD), was predictive of allograft survival (n=224; Log rank P<0.01; pIBD<0.1 vs > 0.1). Notably, pIBD and AGR were not significantly associated with clinical/subclinical rejection at any time post-transplant. In multivariate analysis, lower pIBD scores strongly associated with histologic vascular intimal fibrosis and IF-TA in biopsies obtained less than 1-year (n=199; P<0.01). External validation of these results is ongoing.

Conclusion

Together our novel data show that non-HLA D-R differences determine vascular intimal fibrosis, IF-TA and impact allograft survival.

Funding

  • NIDDK Support